Revenue Beat: Corbion N.V. Beat Analyst Estimates By 6.3%
It's been a good week for Corbion N.V. (AMS:CRBN) shareholders, because the company has just released its latest interim results, and the shares gained 2.9% to €19.61. Results overall were respectable, with statutory earnings of €1.27 per share roughly in line with what the analysts had forecast. Revenues of €337m came in 6.3% ahead of analyst predictions. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.
Taking into account the latest results, the most recent consensus for Corbion from seven analysts is for revenues of €1.28b in 2026. If met, it would imply a satisfactory 2.5% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to leap 28% to €1.39. Yet prior to the latest earnings, the analysts had been anticipated revenues of €1.28b and earnings per share (EPS) of €1.33 in 2026. So the consensus seems to have become somewhat more optimistic on Corbion's earnings potential following these results.
Check out our latest analysis for Corbion
The consensus price target was unchanged at €23.30, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Corbion, with the most bullish analyst valuing it at €26.00 and the most bearish at €19.50 per share. Still, with such a tight range of estimates, it suggeststhe analysts have a pretty good idea of what they think the company is worth.
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. The analysts are definitely expecting Corbion's growth to accelerate, with the forecast 5.0% annualised growth to the end of 2026 ranking favourably alongside historical growth of 2.2% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 3.3% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Corbion to grow faster than the wider industry.
The Bottom Line
The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Corbion following these results. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for Corbion going out to 2028, and you can see them free on our platform here.
You should always think about risks though. Case in point, we've spotted 2 warning signs for Corbion you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.